Boehringer's Empagliflozin Heads To Advisory Cmte. With Questions On Treatment Effect

 
• By Michael Cipriano
  
Diabetes
A US FDA advisory committee will assess Boehringer Ingelheim's empagliflozin for a type 1 diabetes indication.

More from US FDA Performance Tracker

More from Regulatory Trackers